Literature DB >> 12215019

Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases.

Keiko Fujii1, Masako Aoyama, Katsuji Shinagawa, Keitaro Matsuo, Katsuto Takenaka, Kazuma Ikeda, Kensuke Kojima, Fumihiko Ishimaru, Katsuyuki Kiura, Hiroshi Ueoka, Kenji Niiya, Mitsune Tanimoto, Mine Harada.   

Abstract

Autologous peripheral blood stem cell transplantation (auto-PBSCT) has facilitated high-dose chemotherapy for the treatment of various types of malignancy, but the factors affecting the treatment outcome have not been well defined. We evaluated patients who underwent auto-PBSCT (46 patients with hematological malignancies and 39 with solid tumors) to elucidate the risks of background factors, including age, in association with infectious complications. In contrast to former reports, faster engraftment did not influence the incidence of documented infection or neutropenic fever, whereas high age (age > or = 50 years old) and delayed platelet recovery (> or = 18 days) were demonstrated to be positively involved. The odds ratio (OR) for documented infection in elderly patients was 4.94 (95% confidence interval, 1.22-15.8). Another risk factor of infection was the HD-ICE regimen (ifosfamide, carboplatin, etoposide) given to patients with solid tumors (OR, 8.00; 95% confidence interval, 1.61-39.7). In conclusion, we found that elderly patients and patients on the HD-ICE regimen have a higher risk of infectious complications even after auto-PBSCT. Although the clinical indications for auto-PBSCT can be extended to elderly patients, thorough precautions should be taken against infectious complications during the pre-engraftment phase.

Entities:  

Mesh:

Year:  2002        PMID: 12215019     DOI: 10.1007/BF02982583

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Authors:  R Salazar; C Solá; P Maroto; J M Tabernero; J Brunet; G Verger; V Valentí; J A Cancelas; B Ojeda; L Mendoza; M Rodríguez; J Montesinos; J J López-López
Journal:  Bone Marrow Transplant       Date:  1999-01       Impact factor: 5.483

2.  Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.

Authors:  H Gondo; M Harada; T Miyamoto; K Takenaka; K Tanimoto; S Mizuno; T Fujisaki; K Nagafuji; S Hayashi; T Eto; S Taniguchi; K Akashi; N Harada; K Yamasaki; T Shibuya; E Matsuishi; Y Ohno; S Makino; Y Takamatsu; M Murakawa; T Teshima; Y Hirota; T Okamura; N Kinukawa; Y Niho
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

3.  Early infectious complications in autologous bone marrow transplantation: a review of 219 patients.

Authors:  S B Mossad; D L Longworth; M Goormastic; J M Serkey; T F Keys; B J Bolwell
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

4.  Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies.

Authors:  H Celebi; H Akan; E Akçağlayan; C Ustün; M Arat
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

5.  The problem of thrombocytopenia after hematopoietic stem cell transplantation.

Authors:  R A Nash; T Gooley; C Davis; F R Appelbaum
Journal:  Stem Cells       Date:  1996       Impact factor: 6.277

6.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.

Authors:  L B To; M M Roberts; D N Haylock; P G Dyson; A L Branford; D Thorp; J Q Ho; G W Dart; N Horvath; M L Davy
Journal:  Bone Marrow Transplant       Date:  1992-04       Impact factor: 5.483

7.  Infectious morbidity associated with long-term use of venous access devices in patients with cancer.

Authors:  J S Groeger; A B Lucas; H T Thaler; H Friedlander-Klar; A E Brown; T E Kiehn; D Armstrong
Journal:  Ann Intern Med       Date:  1993-12-15       Impact factor: 25.391

8.  Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation.

Authors:  B Gordon; S Tarantolo; E Ruby; L Stephens; J Lynch; A Kessinger; W Haire
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

9.  Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation.

Authors:  K Larsson; B Björkstrand; P Ljungman
Journal:  Support Care Cancer       Date:  1998-07       Impact factor: 3.603

10.  High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

Authors:  W Siegert; J Beyer; I Strohscheer; H Baurmann; H Oettle; J Zingsem; R Zimmermann; C Bokemeyer; H J Schmoll; D Huhn
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

View more
  1 in total

1.  C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Authors:  Vidya Kollu; Sarah L Mott; Rafiullah Khan; Umar Farooq; Yogesh Jethava; Ince Dilek; Guido Tricot
Journal:  Cureus       Date:  2018-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.